Bifunctional bet binding compounds and uses thereof
WO2026122568A3PCT designated stage Publication Date: 2026-07-23PHOTYS THERAPEUTICS INC
View PDF 0 Cites 0 Cited by
Patent Information
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- PHOTYS THERAPEUTICS INC
- Filing Date
- 2025-12-02
- Publication Date
- 2026-07-23
AI Technical Summary
Technical Problem
Existing treatments for cancer, particularly p53 mutant cancer cells, are inadequate in inducing sufficient gene expression and apoptosis, limiting their therapeutic efficacy.
Method used
Development of bifunctional molecules that link a targeting moiety to a BET-binding moiety through a chemical linker, forming a ternary complex to enhance gene expression and induce apoptosis in cancer cells.
Benefits of technology
The bifunctional molecules demonstrate a synergistic increase in gene expression and apoptosis, effectively changing the fate of cancer cells from cell cycle inhibition to apoptosis, providing a potent therapeutic modality for cancer treatment.
✦ Generated by Eureka AI based on patent content.
Abstract
Provided herein are heterobifunctional compounds that bind a targeting moiety (e.g., a transcription factor) and a BET protein. The compounds selectively inhibit proliferation and induce apoptosis of cells. Also provided are compounds that are synthetic intermediates of the bifunctional compounds. Also provided are pharmaceutical compositions comprising the disclosed compounds and methods of treating a disease or condition by administering a compound or composition described herein.
Need to check novelty before this filing date? Find Prior Art